Orion Oyj B (ORNBV)
Nasdaq Helsinki · Finland · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 95.75 |
|---|---|
| 52-week range | 56.50 – 97.80 |
| Return, 1 month / 3 months | +15.4% / +20.4% |
| Return, 1 year / 3 years | +42.3% / +186.3% |
| Trend | Uptrend |
| RSI (14) | 79 |
| Volatility (1 year) | 32.8% |
| Worst drawdown (1 year) | -16.8% |
| Average daily value traded | 13.05M EUR |
| Dividend yield | 1.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Orion is a Finnish pharmaceutical company based in Espoo that develops, manufactures and markets prescription medicines and active pharmaceutical ingredients. Its product range covers treatments for central nervous system disorders, oncology and respiratory conditions, along with inhaler devices and veterinary medicines. Orion serves healthcare professionals, hospitals and pharmacies, and it also supplies pharmaceutical ingredients to other drug makers. Its medicines are used in Finland and exported to many other countries.
Orion Oyj B trades under the code ORNBV on the Nasdaq Helsinki in Finland, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Orion Oyj B (ORNBV) trades on the Nasdaq Helsinki in Finland. It last closed at EUR 95.75 on 27 October 2026.
Its price-based Market X-Ray is 80 out of 100 (a strong price profile), ranking 6 of 190 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 42.3% and over the last three months it rose 20.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Nasdaq Helsinki
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 93 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 29.5% | ||
| From 52-week high | -0.6% | ||
| Momentum | 86 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 20.4% | ||
| 6-month return | 41.3% | ||
| 12-month return, skipping the last month | 23.3% | ||
| Stability (higher is calmer) | 69 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 32.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -16.8% | ||
| Liquidity | 94 · Strong | Trades actively. | |
| Average daily value traded | 13.05M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 40 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.9% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +8.4% |
|---|---|
| 1 month | +15.4% |
| 3 months | +20.4% |
| 6 months | +41.3% |
| 1 year | +42.3% |
| 3 years | +186.3% |
| 5 years | +197.4% |
Signals
| 50-day / 200-day average | 82.69 / 73.96 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.19 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 Oct 2026 | EUR 0.9000 |
| 25 Mar 2026 | EUR 0.9000 |
| 15 Oct 2025 | EUR 0.8200 |
| 4 Apr 2025 | EUR 0.8200 |
| 15 Oct 2024 | EUR 0.8100 |
| 21 Mar 2024 | EUR 0.8100 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Nasdaq Helsinki; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.